A chronic inflammatory bowel disease limited to the colon and rectum, causing ulcers and bloody diarrhoea.
✦ AI summary
Research on ulcerative colitis (UC) is exploring several angles:
- **Gut microbiome and inflammation**: Studies suggest UC involves disrupted gut bacteria and an overactive immune response in the gut lining, though it's unclear whether microbiome changes cause the inflammation or result from it [2]. Lab models show that fecal-derived substances from patients with active UC (but not those in remission) can trigger inflammatory signals and damage to gut tissue models [2]. A probiotic bacteria (E. coli Nissle 1917) given to UC patients showed changes in gut bacteria diversity and some improvement in intestinal permeability [6].
- **Experimental/natural compound treatments**: Several early-stage studies test plant-derived or synthetic compounds in animal models of colitis. These include a flavonoid called baicalein, reformulated to improve absorption, which reduced inflammation and colon damage in mice [1]; a Chinese herbal capsule and its active ingredient polydatin, which affected immune cell balance and reduced inflammation in mouse and human tissue samples [4]; an herbal granule formula (GQG) that altered gut bacteria and reduced inflammatory signaling in m
This is an AI-generated summary of the sources below — not medical advice. Always talk to a doctor or pharmacist about your own situation.
Assessing the proinflammatory potential of sterile fecal microbiome filtrate from ulcerative colitis patients using an intestine-on-chip platform and automated image analysis.
Ulcerative colitis (UC) is characterized by disruptions of the gut microbiome and an exaggerated mucosal immune response in genetically susceptible individuals. Alterations in the composition of the intestinal metabolome associated with dysbiosis can trigger chronic inflammation. However, it remains…
Baicalein solid dispersion prepared by solvent evaporation enhances oral bioavailability and alleviates ulcerative colitis.
Baicalein (BAC) is a flavonoid compound known for its effectiveness in treating ulcerative colitis (UC). However, its clinical application is limited by poor water solubility, low stability, and low oral bioavailability. In this study, a baicalein solid dispersion (BAC-SD) was prepared using Polyvin…
The relationship between the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and tubular atrophy/interstitial fibrosis in patients with IgA nephropathy.
Background: The tubular atrophy/interstitial fibrosis (T) lesions of the Oxford Classification is a key prognostic determinant in IgA nephropathy (IgAN). The non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) is an emerging lipid marker, but its link with r…
Management of Clostridioides difficile Infection in Patients with Inflammatory Bowel Disease.
Clostridioides difficile is a gram-positive, anaerobic bacteria that is ubiquitous. Oral-fecal transmission of the organism and its spores leads to C difficile colonization and infection (CDI) within the human gastrointestinal tract. Patients with inflammatory bowel disease (IBD) are more likely to…
Hudi enteric-coated capsule and its active constituent polydatin suppress Th1/Th17-mediated intestinal inflammation by modulating the KEAP1-NFE2L2 signaling pathway.
To investigate the anti-inflammatory mechanisms of Hudi enteric-coated capsule (HDEC) and its major bioactive constituent, polydatin, in ulcerative colitis (UC). Mouse models of colitis were established by transplantation adoptive transfer of CD45RBhighCD4+ T cells and treated with or without HDEC/p…
Oral Health of Patients With Inflammatory Bowel Disease-A Cross-Sectional Survey in Austria.
This cross-sectional survey aimed to assess oral health in patients with inflammatory bowel diseases (IBD) living in Austria. Data collection was conducted with an online questionnaire, including when possible validated tools, covering general medical history, socioeconomic factors, IBD-related para…
The effects of Escherichia coli Nissle 1917 on the gut microbiota composition in ulcerative colitis patients.
Escherichia coli Nissle (EcN) 1917 is a Gram-negative bacterium currently used as probiotic in the management of infectious gastroenteritis and ulcerative colitis (UC). We evaluated the effect of administration of EcN on the composition of the gut microbiota and on intestinal permeability in patient…
Proximally dominant inflammation at colonoscopy predicts pan-colonic histological remission following oral vancomycin therapy in pediatric ulcerative colitis.
Oral vancomycin therapy (OVT) induces histological remission in children with ulcerative colitis (UC) showing primary sclerosing cholangitis (PSC)-associated features (proximally dominant or patchy inflammation, backwash ileitis, or rectal sparing). However, predictors of response and optimal treatm…